William Blair Investment Management LLC lowered its position in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 81.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 323,280 shares of the biopharmaceutical company’s stock after selling 1,387,641 shares during the quarter. William Blair Investment Management LLC’s holdings in Bristol-Myers Squibb were worth $18,013,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. State Street Corp raised its holdings in shares of Bristol-Myers Squibb by 1.8% during the first quarter. State Street Corp now owns 68,893,779 shares of the biopharmaceutical company’s stock valued at $3,746,446,000 after purchasing an additional 1,223,457 shares during the period. Jennison Associates LLC raised its holdings in shares of Bristol-Myers Squibb by 5.4% during the second quarter. Jennison Associates LLC now owns 23,118,789 shares of the biopharmaceutical company’s stock valued at $1,288,179,000 after purchasing an additional 1,184,652 shares during the period. Ameriprise Financial Inc. raised its holdings in shares of Bristol-Myers Squibb by 18.7% during the first quarter. Ameriprise Financial Inc. now owns 15,547,051 shares of the biopharmaceutical company’s stock valued at $845,504,000 after purchasing an additional 2,451,390 shares during the period. Legal & General Group Plc raised its holdings in shares of Bristol-Myers Squibb by 2.7% during the second quarter. Legal & General Group Plc now owns 8,431,348 shares of the biopharmaceutical company’s stock valued at $469,802,000 after purchasing an additional 217,920 shares during the period. Finally, Swiss National Bank raised its holdings in shares of Bristol-Myers Squibb by 27.2% during the first quarter. Swiss National Bank now owns 5,921,670 shares of the biopharmaceutical company’s stock valued at $322,020,000 after purchasing an additional 1,267,900 shares during the period. 68.93% of the stock is currently owned by institutional investors and hedge funds.

In other Bristol-Myers Squibb news, SVP Joseph C. Caldarella sold 9,340 shares of Bristol-Myers Squibb stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total value of $560,400.00. Following the completion of the transaction, the senior vice president now directly owns 46,297 shares of the company’s stock, valued at $2,777,820. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.23% of the stock is currently owned by insiders.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.77 by ($0.02). The firm had revenue of $5.25 billion during the quarter, compared to analysts’ expectations of $5.20 billion. Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The firm’s quarterly revenue was up 6.7% on a year-over-year basis. During the same period last year, the firm posted $0.77 earnings per share.

The company also recently announced a quarterly dividend, which was paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th were issued a $0.39 dividend. The ex-dividend date was Thursday, October 5th. This represents a $1.56 annualized dividend and a yield of 2.51%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 61.42%.

BMY has been the topic of several research reports. Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and set a $63.00 price objective on shares of Bristol-Myers Squibb in a report on Wednesday, August 9th. Vetr lowered shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $63.81 price objective on the stock. in a report on Wednesday, August 9th. Jefferies Group LLC reiterated a “buy” rating and set a $63.00 price objective on shares of Bristol-Myers Squibb in a report on Wednesday, July 12th. Finally, UBS AG reiterated a “buy” rating and set a $72.00 price objective (up previously from $62.00) on shares of Bristol-Myers Squibb in a report on Friday, October 6th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and eleven have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $64.93.

TRADEMARK VIOLATION WARNING: This article was originally published by Watch List News and is the property of of Watch List News. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://www.watchlistnews.com/bristol-myers-squibb-company-bmy-shares-sold-by-william-blair-investment-management-llc/1674721.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with Analyst Ratings Network's FREE daily email newsletter.